TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05816915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Subjects will receive professional lifestyle intervention conducted by STOB organization. Using CBT and the so-called third wave of CBT, especially mindfulness, the patients will be guided by certified experts to increase motivation and to change eating and exercise habits, which will be mapped before and after the intervention.
Study: NCT06128018

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical gastrojejunostomy (S-GJ)
Description: Surgical gastro-jejunostomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EUS-guided gastrojejunostomy (EUS-GJ)
Description: Endoscopic Ultrasound guided gastro-jejunostomy
Study: NCT06420388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine Gel
Description: The intervention group received 5 mL of 2% lidocaine gel applied topically 3 times per day after undergoing Ferguson hemorrhoidectomy surgery.~The control group received 5 mL of a non-anesthetic water-based lubricant gel applied topically 3 times per day after surgery.~The application of the gels began immediately after surgery and continued for the postoperative period evaluated in the study.~Both groups received standard postoperative analgesics (acetaminophen, celecoxib, Dynastat/parecoxib as needed) in addition to the topical gel applications.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water-based Lubricant Gel (K-Y Gel)
Description: The intervention group received 5 mL of mL of a non-anesthetic water-based lubricant gel (K-Y gel) applied topically 3 times per day after undergoing Ferguson hemorrhoidectomy surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Postoperative Analgesics
Description: Acetaminophen (Paracetamol)~Dosage: 500 mg per tablet Frequency: Every 6 hours Route: Oral~Acetaminophen is a common over-the-counter pain reliever and fever reducer. It works by blocking the production of prostaglandins, which are responsible for causing pain and inflammation.~Celecoxib~Dosage: 200 mg per tablet Frequency: Every 12 hours Route: Oral~Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that specifically inhibits the cyclooxygenase-2 enzyme. By reducing the production of prostaglandins, celecoxib helps alleviate pain and inflammation.~Dynastat (Parecoxib)~Dosage: 40 mg per injection Frequency: Every 12 hours as needed for poorly controlled pain Route: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Postoperative Analgesics
Description: Acetaminophen (Paracetamol)~Dosage: 500 mg per tablet Frequency: Every 6 hours Route: Oral~Acetaminophen is a common over-the-counter pain reliever and fever reducer. It works by blocking the production of prostaglandins, which are responsible for causing pain and inflammation.~Celecoxib~Dosage: 200 mg per tablet Frequency: Every 12 hours Route: Oral~Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that specifically inhibits the cyclooxygenase-2 enzyme. By reducing the production of prostaglandins, celecoxib helps alleviate pain and inflammation.~Dynastat (Parecoxib)~Dosage: 40 mg per injection Frequency: Every 12 hours as needed for poorly controlled pain Route: Intravenous
Study: NCT05140226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Training
Description: Eight weeks of home-based physical exercise training. Aerobic training will be performed 5 times per week using a foot peddler for a minimum of 30 minutes at a moderate intensity (Borg Exertion Scale: between 4 and 6; pedaling speed: 50 RPM). Strength training will be performed 2 times per week, with 1-3 sets of 10-12 repetitions per exercise. Strength exercises will include training with resistance bands and bodyweight exercises. Participants will be instructed to reduce the intensity of their training if they reach a score of 7 on the Borg Exertion Scale, if oxygen saturation is less than 85%, or if they experience any symptoms. Exercise prescriptions will be developed and monitored by an exercise professional with weekly follow-up meetings and supported with a web application (Physiotec) that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Training
Description: Eight weeks of home-based physical exercise training. Aerobic training will be performed 5 times per week using a foot peddler for a minimum of 30 minutes at a moderate intensity (Borg Exertion Scale: between 4 and 6; pedaling speed: 50 RPM). Strength training will be performed 2 times per week, with 1-3 sets of 10-12 repetitions per exercise. Strength exercises will include training with resistance bands and bodyweight exercises. Participants will be instructed to reduce the intensity of their training if they reach a score of 7 on the Borg Exertion Scale, if oxygen saturation is less than 85%, or if they experience any symptoms. Exercise prescriptions will be developed and monitored by an exercise professional with weekly follow-up meetings and supported with a web application (Physiotec) that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Physical Training
Description: Eight weeks of home-based cognitive and physical training. Cognitive training sessions will be performed 5 times per week using the Brain HQ platform (Posit Science; San Francisco, CA, USA) and will have a duration of approximately 60 minutes. The cognitive training program will be tailored by using the Personal Trainer function which presents an automated sequence of exercise levels to participants based on selected exercises. Participants will have identical sessions initially, but schedules will diverge as participants progress and as the algorithm considers their individual performance history. The Personal Trainer program will be customized to the abilities of each user and will include a focus on the following domains: sustained attention, executive function, short and long-term memory, and anxiety and depression. Participants in this group will also engage in the same exercise training intervention as participants in the Physical Training group.
Study: NCT06224062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2
Description: Circulating strains of SARS-CoV-2 (including variants of concern) were already collected, cultured and purified. The Wuhan reference strain will be used in the VIRCHILLD study to infect cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2
Description: Circulating strains of SARS-CoV-2 (including variants of concern) were already collected, cultured and purified. The Wuhan reference strain will be used in the VIRCHILLD study to infect cells.
Study: NCT05006378

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chamomile Tea
Description: Chamomile tea bags consumed by subjects as described in study arms section.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chamomile Extract Capsule
Description: Chamomile extract capsules consumed by subjects as described in Experimental: Chamomile Extract Capsule study arms section.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Placebo capsules consumed by subjects as described in Placebo Comparator study arms section.
Study: NCT04756622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N acetyl cysteine
Description: N acetyl cysteine dissolved in water at a dose of 600 mg three times daily from day of transplant until neutrophil engraftment, or upon resolution of OM, whichever appears later.
Study: NCT05570552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth based behavioral change communication intervention
Description: We will implement a mHealth based communication system. The number of text messages and push notifications that a participant receives, will be variable and will occur at least weekly (based upon their responses) or the participant opts out of receiving messages. Participant change of behavior and use of improved stoves will be monitored by tracking clicks/views of educational materials and video vignettes.
Study: NCT05042817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg morphine
Description: The effect of intrathecal morphine on vesical function and the need for bladder re-catheterization after a cesarean delivery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: NaCl 0.9%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg prilocaine + 2.5 mcg sufentanil
Description: 50 mg prilocaine + 2.5 mcg sufentanil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 50 mg prilocaine + 2.5 mcg sufentanil
Description: 50 mg prilocaine + 2.5 mcg sufentanil

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: bilateral transverse abdominal plane block
Description: 20 mL of ropicavaine 0.375% on each side
Study: NCT06224062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2
Description: Circulating strains of SARS-CoV-2 (including variants of concern) were already collected, cultured and purified. The Wuhan reference strain will be used in the VIRCHILLD study to infect cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus (AdV)
Description: Infection with C-type viruses (e.g. HAd-C5) using bronchial epithelium from adult donors

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus (AdV)
Description: Infection with C-type viruses (e.g. HAd-C5) using bronchial epithelium from adult donors

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus (AdV)
Description: Infection with C-type viruses (e.g. HAd-C5) using bronchial epithelium from adult donors

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rhinovirus
Description: RV is a member of the picornaviridae family; small non-enveloped viruses with a single strand positive RNA genome protected by an icosahedral capsid. They are divided in more than 160 serotypes classed in subtype A, B and C. RV-A and RV-C infections will be used in the VIRCHILLD study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rhinovirus
Description: RV is a member of the picornaviridae family; small non-enveloped viruses with a single strand positive RNA genome protected by an icosahedral capsid. They are divided in more than 160 serotypes classed in subtype A, B and C. RV-A and RV-C infections will be used in the VIRCHILLD study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rhinovirus
Description: RV is a member of the picornaviridae family; small non-enveloped viruses with a single strand positive RNA genome protected by an icosahedral capsid. They are divided in more than 160 serotypes classed in subtype A, B and C. RV-A and RV-C infections will be used in the VIRCHILLD study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: no infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: no infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: no infection
Study: NCT06052137

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TBS-DLPFC
Description: Participants will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TBS-DMPFC
Description: Participants will receive intermittent TBS to DMPFC. The DMPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the DMPFC using a MagPro TMS system (MagVenture, Denmark).
Study: NCT04447508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participants receive one on one motivational interviewing and participate in a group exercise class virtually.
Description: Participants have one group exercise class over zoom per week and an online one on one motivational interviewing session every second week.
Study: NCT05432336

Intervention type: DIAGNOSTIC_TEST
Intervention: NGS for endohtalmitis / Multiplex PCR for keratitis
Description: For endophtalmitis : optimizing culture and NGS will be realized~For keratitis: Multiplex PCR will be added on ocular samples
Study: NCT05183529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitals Monitoring Pill System
Description: The Celero Vitals Monitoring Pill (VM Pill) uses 3 axis accelerometry to measure physiological signals from within the GI tract.
Study: NCT04632459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab plus ramucirumab
Description: Patients will continue to receive study treatment, until they demonstrate objective disease progression (determined by modified RECIST 1.1) or until they meet any other discontinuation criteria.~* Ramucirumab 8mg/kg on q2W~* Pembrolizumab 200mg on q3W (pembrolizumab first followed by ramucirumab when concurrently administered on the same day)~* If ramucirumab had to be stopped due to intolerable toxicity, pembrolizumab will be continued until unacceptable toxicity, disease progression or upto 35 cycles.
Study: NCT05191719

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botox injection
Description: Comparator, current gold standard

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botox injection
Description: Comparator, current gold standard

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurotomy
Description: Surgical procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurotomy
Description: Surgical procedure
Study: NCT06392035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health education, web-based education
Description: Data collection tools will be filled in by two study groups (experimental group, control group) and based on the pre-test results of both groups, Pender\&#39;s SGM-based breakfast training will be given only to the experimental group. No intervention will be made to the control group. In this study, a total of 6 sessions will be held for the experimental group for 6 weeks (one session per week), each lasting 40 minutes. In these sessions, web-based training will be given every week according to the components of the model and will be supported with written and visual brochures.
Study: NCT04776928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Push reports
Description: Surgeons in the experimental arm will receive provider-level push report notifications through an email displaying their personal prescribing performance compared to Michigan Opioid Prescribing Engagement Network (OPEN) prescribing guidelines and their de-identified peers.~The push report will also include a link to the secure MSQC data platform that displays more information about the case so the surgeon can further investigate prescribing information. The email will also contain contact information for the study team so as to help any surgeons troubleshoot, learn more, request to stop receiving reports, etc.
Study: NCT05589896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ossium HPC Marrow, Bone Marrow Transplant
Description: Hematopoetic Cell Transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ossium HPC Marrow, Bone Marrow Transplant
Description: Hematopoetic Cell Transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-transplant conditioning - Myeloablative (MAC)
Description: Regimen A or Regimen B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-transplant conditioning - Myeloablative (MAC)
Description: Regimen A or Regimen B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-transplant conditioning - Reduced Intensity (RIC)
Description: Regimen C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-transplant treatment
Description: Post-transplant treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-transplant treatment
Description: Post-transplant treatment
Study: NCT05089578

Intervention type: OTHER
Intervention: focus interview
Description: The Information Form including descriptive characteristics of the individuals undergoing Covid-19, the semi-structured Interview Form, and the Complementary Therapy Use Form were used as the data collection tools. The Information Form consisted of 13 questions including socio-demographic and disease-related characteristics of individuals. In-depth interview method was used to collect data. Interviews were held by organizing video calls and online meeting programs on mobile phones both due to pandemic measures and in order to enable individuals to communicate comfortably. The time period in which the individuals felt most ready for the interview was determined and the data were collected during that time. During the interview, effective communication techniques were used, active listening was carried out and individuals were guided using question forms in accordance with the aim of the study. The interviews lasted for an average of 25-30 minutes.
Study: NCT06286917

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIV initiation in patients with ALS
Description: NIV initiation according to standard care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIV initiation in patients with ALS
Description: NIV initiation according to standard care
Study: NCT05945238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrower's Ten Exercise Program
Description: T10 group were given thrower's ten exercises 3 times per week for 10 weeks, each exercise being 2x10 repetitions.
Study: NCT05013216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A: Patients at high risk of developing pancreatic cancer.
Description: 1. KRAS peptide vaccine with poly-ICLC adjuvant will be administered on Prime week 1, 3, and 5. Boost vaccinations with will be administered at week 13. All subjects will return to the study site approximately 28 days (+ 7 days) after the last vaccination for an End of Treatment (EOT) and safety evaluation.~2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort B: Patients must have evidence of a pancreatic cystic neoplasm
Description: Patients will receive KRAS peptide vaccine with poly-ICLC adjuvant as two prime vaccinations on weeks 1 and 2. Surgery is considered standard of care. Surgery will occur at the discretion of the treating hepatobiliary surgeon and is not dictated by this protocol. Subjects will return to the study site approximately at week 4 (+ 7 days) for a safety evaluation prior to surgery. Subjects will have an End of Treatment (EOT) visit at study Week 8 (+ 7 days).
Study: NCT05874232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Program through Heartfulness
Description: A four-week Self-Care program through Heartfulness will be offered to participants in the Heartfulness group. This would include a daily practice of relaxation tools for 15 minutes a day using an app and once a weekly webinar for 30 minutes. Guided relaxation and meditation sessions will be offered to the participants during the intervention weeks. These virtual sessions were conducted by Heartfulness Champions and certified trainers from Heartfulness Institute.
Study: NCT06127277

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Next4You
Description: Youth in the intervention arm will have access for four continuous weeks to a mobile intervention that covers topics related to communication, relationships, sexual wellness, contraception, respecting self and partners, and building wealth and wellness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Next4You
Description: Youth in the intervention arm will have access for four continuous weeks to a mobile intervention that covers topics related to communication, relationships, sexual wellness, contraception, respecting self and partners, and building wealth and wellness.
Study: NCT05406414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic sleep and circadian treatment
Description: The intervention group receives sleep treatment consisting of 6 sessions of 60 minutes each over 6 weeks. The sessions are delivered individually and have the following content:~1. Assessment and introduction to the sleep diary~2. Review of sleep diary - agreements on behavior changes and goals.~3. Information on normal sleep, sleep problems and circadian rhythm~4. Cognitive techniques~5. Introduction to relaxation training~6. Follow-up on goals and plan for prevention relapse of sleep problems

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active waitlist control group
Description: The control group receives sleep hygiene education consisting of a single session in which 10 points of sleep advice are presented. They receive a booklet on how to promote good sleep practice and must work on their own for the next 6 weeks to implement this while waiting for the intervention.
Study: NCT05427435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marshall ethanolisation
Description: Destruction of Marshall bundles by ethanol 96% infusion (3 separate injections of 3.3ml)
Study: NCT05194462

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pericoach® by Analytica
Description: This intervention will assess urinary incontinence-related quality of life in postpartum women with self-reported urinary incontinence who are randomized to a program of home biofeedback .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Physical Therapy
Description: This intervention will assess urinary incontinence-related quality of life in postpartum women with self-reported urinary incontinence who are randomized to a program of PFPT.
Study: NCT05550636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam
Study: NCT05667662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole Powder
Description: Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole Powder
Description: Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules with 11.8 mg total powder (excipients only)
Study: NCT05324319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad26COVS1
Description: Heterologous vaccination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChAdOx1 SARS2 Vaccine
Description: Heterologous vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNT162B2
Description: Homologous vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: Homologous vaccination